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INTRODUCTION
Gastric cancer is one of the leading causes of death in the
world. Metastasis to the regional lymph node is an indicator
of tumor progression as well as an important prognostic fac-
tor in gastric cancer. Recent evidence suggests that tumor
lymphangiogenesis promotes lymphatic metastasis (1-3). How-
ever, little is known about the mechanism of lymphangio-
genesis in gastric carcinoma.
Vascular endothelial growth factor (VEGF)-C and VEGF-
D are the best-characterized lymphangiogenic growth factors.
These growth factors stimulate lymphangiogenesis by acti-
vating VEGF receptor (VEGFR)-3, also known as Flt (fms-
like tyrosine kinase)-4, a receptor which is expressed in the
lymphatic endothelium (4-7). VEGFR-3 was once thought
to be a marker of lymphatic endothelial cells because it is
mainly expressed in the lymphatic endothelium of adult tis-
sue (8); however, VEGFR-3 has also been detected in blood
vessels within tumors and wounds that are healing (9, 10). 
Several studies have correlated VEGF-D expression with
lymph node metastasis in a variety of cancers including col-
orectal (11), breast (12), pancreatic (13), ovarian (14), and
endometrial (15). Furthermore, a high VEGFR-3-positive
vessel density has been correlated with poor prognosis in
breast cancer (16) and non-small cell lung cancer (17).
The role of VEGF-D and VEGFR-3 in gastric carcinoma
has not been fully determined. Recently, Jutter et al. report-
ed that VEGF-D and VEGFR-3 are novel independent prog-
nostic marker molecules for reduced survival after the cura-
tive resection of gastric adenocarcinoma (18). The goal of our
study was to investigate the clinical value of VEGF-D expres-
sion and VEGFR-3-positive vessel density in gastric carcino-
ma with regard to lymphangiogenesis.
MATERIALS AND METHODS
Study population and tissue samples
This study comprised 104 patients who underwent surgi-
cal resection for gastric adenocarcinoma at Hanyang Univer-
sity Guri Hospital between April 2000 and November 2003.
Of those, 84 patients had advanced gastric cancers and 20
patients had early gastric cancers. Well-documented clinical
data were collected from all patients. Information concerning
the date of initial diagnosis, clinical characteristics, relapse,
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Correlation of Vascular Endothelial Growth Factor-D Expression and
VEGFR-3-Positive Vessel Density with Lymph Node Metastasis in
Gastric Carcinoma
Lymph node metastasis is an important prognostic factor in gastric cancer. Vascu-
lar endothelial growth factor-D (VEGF-D) is a lymphangiogenic growth factor that
activates VEGF receptor (VEGFR)-3, a receptor expressed in the lymphatic endothe-
lium. We investigated the clinical value of VEGF-D expression and VEGFR-3 posi-
tive vessel density in gastric carcinoma with regard to lymphangiogenesis. Immuno-
histochemical staining was used to determine the expression of VEGF-D and VEGFR-
3 in specimens from 104 cases of resected gastric cancer. VEGF-D expression was
observed in 62.5% of the gastric cancers and in 9.6% of the non-neoplastic gastric
tissue. The VEGFR-3-positive vessel density was significantly greater in the VEGF-
D positive group than the negative group. VEGF-D expression was significantly
associated with lymph node metastasis, increased serum CEA levels, and the non-
signet ring cell type. The VEGFR-3-positive vessel density was correlated with tumor
size, lymphatic invasion, and lymph node metastasis. The VEGF-D expression and
high VEGFR-3-positive vessel density were significant poor prognostic factors for
relapse-free survival. These results suggest that VEGF-D and VEGFR-3-positive
vessel density are potential molecular markers that predict lymphatic involvement
in gastric carcinoma.
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and death were retrospectively obtained. In addition, adjacent
non-neoplastic stomach tissue samples as confirmed by Hema-
toxylin and Eosin staining were used as controls. This study
was approved by the institutional review board of Hanyang
University Guri Hospital.
Immunohistochemistry
The avidin-biotin complex (ABC) method was used for
immunostaining. Formalin-fixed, paraffin-embedded tissue
blocks were sectioned at a 4- m thickness. The tissue sections
were deparaffinized by three, 10-min incubations in xylene
and then rehydrated in serial graded alcohol. For antigen re-
trieval, the sections were heated in a microwave oven for 10
min in 10 mM/L sodium citrate buffer (pH 6). Endogenous
peroxidase activity was eliminated by preincubation in 3%
hydrogen peroxide and 10% methanol for 15 min followed
by three washes in phosphate-buffered saline. All slides were
pre-incubated at 37℃ for 20 min with two drops of normal
blocking solution (goat serum, 100  L/slide). The slides were
then incubated with either a goat polyclonal anti-VEGF-D
antibody (R&D Systems, Minneapolis, MN) at a 1:100 dilu-
tion overnight at 4℃ or a rabbit polyclonal anti-VEGFR-3
antibody (Zymed Laboratories, San Francisco, CA, U.S.A.)
at a 1:200 dilution for 2 hr at room temperature. Biotinylat-
ed secondary antibody was added to each slide and incubat-
ed for 30 min at 37℃. The slides were then treated with the
avidin-biotinylated peroxidase complex (Immunotech, Cedex,
France) for an additional 30 min at room temperature. 3, 3’-
diaminobenzidine tetrahydrochloride (Immunotech, Cedex,
France) was used for color development. Finally, the sections
were counterstained with hematoxylin.
Evaluation of staining
All slides were coded and evaluated by two experienced
pathologists without knowledge of patient identity or clini-
cal status. Each experiment was performed twice independent-
ly. In the discrepant cases, two pathologists reviewed the cases
together and reached a consensus. The VEGF-D staining
intensity was scored as 0 (negative), 1 (weak), 2 (medium),
and 3 (strong). The extent of staining was scored according
to the percentage of areas with positive VEGF-D staining as
follows: 0 (0%), 1 (1 to 25%), 2 (26 to 50%), 3 (51 to 75%),
and 4 (76 to 100%). The final staining score was derived from
the sum of the intensity score and the extent score. Tumors
with a final staining score of ≥5 were considered as positive
for VEGF-D expression.
The VEGFR-3-positive vessel density was assessed accord-
ing to the method described by Weidner et al. (19). Microves-
sel counting was performed twice. Each slide was first scanned
at 100× magnification to determine three “hot spots” defined
as areas with the maximum number of VEGFR-3-positive
vessels. The VEGFR-3-positive vessel density was determined
by counting all the immunostained vessels at a 200× mag-
nification and the mean number of positive vessels was cal-
culated in the three selected areas for each case. 
Statistical analysis
The Pearson chi-square ( 2) test was performed to deter-
mine the correlation between VEGF-D expression and vari-
Fig. 1. Immunohistochemical staining of a gastric carcinoma. Each photograph shows representative tissue that is positive for VEGF-D (A)
and VEGFR-3 (B) (×400).
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ous clinicopathological factors. The Mann-Whitney U test
and Kruskal-Wallis test were used to examine the associa-
tion of VEGFR-3-positive vessel density. Survival curves were
calculated using the Kaplan-Meier method and compared with
other prognostic variables using the log-rank test. A stepwise
Cox’s regression analysis was performed to identify prognostic
factors for survival. In all tests, p<0.05 was considered sta-
tistically significant. All statistical analyses were performed
using SPSS 10
� statistical software.
RESULTS
Patient characteristics
Our study included 71 male (68.3%) and 33 female (31.7
%) patients, with a median age of 59 yr (range, 25-79 yr). All
tumors were staged using the AJCC classification. Forty-three
patients (41.4%) were classified as stage I, 11 patients (10.6%)
as stage II, 20 patients (19.2%) as stage III, and 30 patients
(28.8%) as stage IV. R0 resection was done in 95 patients, R1
resection in 4, and R2 resection in 5. Forty-one patients received
intravenous systemic chemotherapy after surgery (17 patients:
cisplatin+5-fluorouracil (5-FU), 16 patients: heptaplatin
+5-FU, and 8 patients: paclitaxel+cisplatin+5-FU) and
56 patients received 5-fluorouracil orally. The median fol-
low-up period was 35.9 months (range: 2.1-70.5 months).
Thirty-five patients had relapsed by the time of last follow-up
and thirty-five patients died. The most common cause of
death was disease progression (30 patients), while other caus-
es of death included respiratory failure (1 patient), bowel
infarction (1 patient), liver cirrhosis (1 patient), malnutri-
tion (1 patient), and septic shock (1 patient).
VEGF-D expression and correlation with clinicopathological
parameters
A granular pattern of VEGF-D staining was observed with-
in the cytoplasm of malignant gastric epithelium (Fig. 1).
VEGF-D expression was observed in 62.5% of gastric can-
cers and in 9.6% of non-neoplastic gastric tissues (p<0.001).
VEGF-D expression was significantly associated with lymph
node metastasis (p<0.05), increased serum carcino embryonic
antigen (CEA) levels (p<0.05), and the non-signet ring cell
type (p<0.001, Table 1). However, we found no significant
differences in other clinicopathological parameters such as
age, sex, primary tumor size, grade, lymphatic and venous
invasion, depth of tumor invasion (T stage), distant metas-
tasis, intravenous systemic chemotherapy, curative respectabil-
ity (R0/R1, R2), and stage between the VEGF-D-positive
and -negative groups.
No. of
VEGF-D FVD
Factor
cases
positive p median p
(%) (range)
Age 
<60 yr 54 33 (61.1) NS 48.5 (1-140) NS
≥60 yr 50 32 (64.0) 49.5 (0-205)
Size 
<5 cm 41 21 (51.2) NS 46.0 (0-100) <0.05
≥5 cm 63 44 (69.8) 50.0 (3-205)
CEA (n=86)
Normal 69 38 (55.1) <0.05 50.0 (0-140) NS
Increased 17 14  (82.4) 60.0  (33-205)
Histological type
Signet ring cell 38 15 (39.5) <0.001 54.0 (3-140) NS
Others 66 50 (75.8) 48.0 (0-205)
Lymphatic invasion
Negative 55 33  (60.0) NS 44.0  (0-205) <0.05
Positive 49 32 (65.3) 54.0 (3-140)
Venous invasion
Negative 99 61  (61.9) NS 47.0  (0-205) NS
Positive 5 4 (80.0) 80.0 (33-127)
Depth of tumor
T1, T2 62 35 (56.5) NS 46.5 (0-205) NS
T3, T4 42 30 (71.4) 51.5 (3-140)
Lymph node metastasis
Negative 42 21  (50.0) <0.05 38.5  (0-131) <0.05
Positive 62 44  (71.0) 54.0  (3-205)
Metastasis 
M0 95 60 (63.2) NS 47.0 (0-205) NS
M1 9 5 (55.6) 67.0 (10-120)
Stage
I 43 23(53.5) NS 38.0  (0-131) NS
II 11 6 (54.5) 60.0 (8-82)
III 20 17 (85.0) 48.5 (22-205)
IV 30 19 (63.3) 55.0 (3-140)
Table 1. Correlation of VEGF-D and VEGFR-3-positive vessel
density (FVD) with clinicopathological parameters
Fig. 2. Correlation between VEGF-D expression and VEGFR-3-posi-
tive vessel density (FVD).
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VEGF-D, vascular endothelial growth factor-D; VEGFR-3, vascular
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VEGFR-3-positive vessel density
We observed VEGFR-3 expression on endothelial cells.
Most of the VEGFR-3-stained vessels were thin-walled and
did not contain red blood cells (Fig. 1). The VEGFR-3 pos-
itive vessel density was significantly greater in gastric carci-
nomas (median, 49.5; range, 0-205) than in non-neoplastic
tissues (26.0; 0-98). Furthermore, the VEGFR-3-positive
vessel densities were 60.0 (10-205) and 36 (0-100) in the
VEGF-D positive and negative groups, respectively (p<0.001,
Fig. 2). The VEGFR-3 positive vessel density was signifi-
cantly correlated with primary tumor size (p<0.05), lymphat-
ic invasion (p<0.05), and lymph node metastasis (p<0.05,
Table 1). However, there was no significant difference in other
clinicopathological parameters such as age, sex, pathologic
type, grade, venous invasion, depth of tumor invasion, and
distant metastasis.
Prognostic factors
To evaluate the correlation between VEGFR-3-positive
vessel density and patient survival, the patients were divid-
ed into two groups: low (<50) and high VEGFR-3-positive
vessel density (≥50). The cutoff value for each group was
determined by the median VEGFR-3-positive vessel densi-
ty. Univariate analysis showed that tumor size (p<0.001), lym-
phatic invasion (p<0.05), venous invasion (p<0.05), T (p<
0.001), N (p<0.001), M (p<0.001), and curative resectability
(p<0.001) were significant factors for overall survival. How-
ever, VEGF-D expression (p>0.05) and high VEGFR-3-pos-
itive vessel density (p>0.05) did not influence overall survival.
Patients with VEGF-D expression had a significantly short-
er relapse-free survival time compared to patients who were
VEGF-D-negative (5 yr relapse-free survival rate 55.8% vs.
67.6%, p<0.05, Fig. 3). Furthermore, the high VEGFR-3-
positive vessel density group showed a significantly worse
relapse-free survival when compared to the low positive ves-
sel density group (5 yr relapse-free survival rate 48.9% vs.
74.9%, p=0.037, Fig. 3). In addition, increased serum CEA
levels (p<0.05), tumor size (p<0.001), lymphatic invasion
(p<0.001), venous invasion (p<0.05), T-category (p<0.001),
N-category (p<0.001), M-category (p<0.001), and curative
resectability (p<0.001) were significant prognostic factors for
relapse-free survival.
In the multivariate analysis, TNM stage and curative resec-
tability were the independent prognostic factors for disease-
free survival and overall survival. The expression of VEGF-
D and high VEGFR-3-positive vessel density did not influ-
ence survival. 
DISCUSSION
The known lymphangiogenic growth factors VEGF-C and
VEGF-D are structurally similar secreted glycoproteins. These
growth factors induce lymphangiogenesis and angiogenesis
in tissues and tumors by activating VEGFR-3, a receptor ex-
pressed in the lymphatic endothelium of adults, and VEGFR-
2, a receptor expressed in the endothelium of blood vessels.
VEGF-C and VEGF-D are synthesized as proproteins. Sub-
sequently, the propeptides can be proteolytically removed to
generate mature forms consisting of VEGF homology domain
dimers. The full-length forms of VEGF that are initially secret-
ed to activate VEGFR-3 but not VEGFR-2. However, after
proteolytic processing, both VEGF-C and VEGF-D bind
VEGFR-2 and VEGFR-3 with high affinity (20, 21).
Previous work has associated VEGF-C and VEGF-D expres-
sion with cancer progression. In a mouse tumor model, the
expression of VEGF-D in tumor cells stimulated the forma-
tion of intratumoral lymphatics, angiogenesis, tumor growth,
Fig. 3. Relapse-free survival of patients with gastric cancer according to VEGF-D expression (A) and VEGFR-3-positive vessel density (B).
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and metastatic spread of tumor cells via the lymphatic vessels.
This VEGF-D-induced lymphatic spread could be blocked
by an antibody specific for VEGF-D (1). In addition, a recent
study reported that VEGF-C and VEGF-D induced lym-
phangiogenesis in experimental gastric tumors by inducing
VEGFR-3 expression (22). Recently, a clinicopathological
study with 91 cases of resected primary gastric adenocarci-
noma showed that VEGF-D correlated with lymphatic metas-
tasis and decreased survival and that VEGF-D and VEGFR-
3 were independent factors associated with poor survival (18).
However, there are only a few reports regarding the expres-
sion of VEGF-D and VEGFR-3 in gastric cancer. And the
association between VEGF-D/VEGFR-3 and lymph node
metastasis remains even less understood. Some reports have
shown a significant correlation of VEGF-D with lymphatic
invasion or lymph node metastasis (23-25) in gastric cancer,
whereas others have found no relationship between them (26,
27). Furthermore, Yonemura et al. reported that the number
of VEGFR-3-positive vessels was closely related to lymphatic
invasion and lymph node metastasis in primary gastric cancer
(28) and another study showed that the expression of VEGFR-
3 was significantly greater in the node-positive group (26).
However, there was also a study that did not find such corre-
lation (25).
In our study, we found that the VEGF-D expression rate
and VEGFR-3-positive vessel density were significantly greater
in gastric carcinoma tissue than in non-neoplastic tissue and
that VEGF-D expression was associated with VEGFR-3-posi-
tive vessel density. Our work also showed that VEGF-D expres-
sion was significantly related to lymph node metastasis and
that VEGFR-3-positive vessel density was significantly cor-
related with lymphatic invasion, and lymph node metasta-
sis. These results suggest that VEGF-D plays an important
role in lymphangiogenesis and lymph node metastasis through
VEGFR-3 in gastric adenocarcinoma. 
In our study, VEGF-D expression and high VEGFR-3-posi-
tive vessel density were significant prognostic factors for re-
lapse-free survival. However, in our results, VEGF-D expres-
sion and high VEGFR-3-positive vessel density did not influ-
ence overall survival. The discrepancies in the results between
our work and the previous study (18) may be due to differ-
ences in the gastric cancer operation method and the relative-
ly short follow-up duration in our study. Although the pvalue
was not statistically significant, the survival curves according
to VEGF-D expression and VEGFR-3-positive vessel densi-
ty separated as time passed. Therefore, a long-term follow-
up is needed to confirm whether VEGF-D expression and/
or VEGFR-3-positive vessel density are significant prognos-
tic factors. 
A previous study reported that VEGF-D expression was
lower in undifferentiated cancer than in differentiated gas-
tric cancer (23). Although VEGFR-3-positive vessel density
was not significantly different between the two groups, we
also found that VEGF-D expression was lower in carcinomas
of signet ring cell type (39.5%) than in non-signet ring cell
type (75.8%). However, signet ring cell type gastric carci-
nomas usually have high rates of lymph node metastasis as
well as poor prognosis. Although we could not find the rea-
son for these results, we thought that these contradictory
findings might be explained by the low binding affinity of
the antibody to signet ring cell carcinoma via an unexplained
mechanism or by the existence of other cytokines that could
promote lymphangiogenesis. Further studies are needed to
elucidate the cause of this apparent contradiction. 
Lymphangiogenesis is one of the important mechanisms
which contribute to the progression of cancer. Because inhibitors
that block the VEGF-C/VEGF-D/VEGFR-3 signaling path-
way might potentially block lymphangiogenous metastasis,
the VEGF-C/VEGF-D/VEGFR-3 interaction has been exten-
sively investigated as a possible target for cancer treatment.
Potential antilymphangiogenic therapeutics include soluble
versions of VEGFR-3 that bind VEGF-C and VEGF-D, there-
by inhibiting activation of endogenous VEGFR-3, neutral-
izing monoclonal antibodies to VEGF-C and VEGF-D that
inhibit binding to both VEGFR-2 and VEGFR-3, monoclon-
al antibodies to VEGFR-3, and small molecules that inhibit
VEGFR-3 tyrosine kinase or downstream signaling molecules
(21). Some of these agents might provide added benefit for
patients as new molecular targeted therapies.
Our study had several limitations. First, immunohistochem-
ical staining was the only method used to determine VEGF-
D and VEGFR-3 expression. More accurate results could be
obtained by combining the immunohistochemistry results
with data from reverse transcription polymerase chain reac-
tions and western blots. Second, the follow-up duration in
this study was short. Third, the clinical data, including relapse
or survival data, was analyzed retrospectively. Lastly, a rela-
tively small number of patients were examined in this study.
Nevertheless, our results suggest that VEGF-D and VEGFR-
3-positive vessel density are potential molecular markers that
predict lymphatic involvement in gastric carcinoma. These
potential markers could be candidates for a new area of molec-
ular therapeutic targeting for gastric cancer. 
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